Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EPS (Basic): 2020-2025

Historic EPS (Basic) for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$1.01.

  • 4D Molecular Therapeutics' EPS (Basic) fell 27.85% to -$1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.75, marking a year-over-year decrease of 31.58%. This contributed to the annual value of -$2.98 for FY2024, which is 15.50% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its EPS (Basic) stood at -$1.01 for Q3 2025, which was down 3.06% from -$0.98 recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' EPS (Basic) registered a high of -$0.24 during Q3 2023, and its lowest value of -$1.01 during Q3 2025.
  • Its 3-year average for EPS (Basic) is -$0.77, with a median of -$0.79 in 2024.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 90.41% in 2021, then plummeted by 229.17% in 2024.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' EPS (Basic) stood at -$0.85 in 2021, then rose by 1.18% to -$0.84 in 2022, then rose by 8.33% to -$0.77 in 2023, then dropped by 16.88% to -$0.90 in 2024, then declined by 27.85% to -$1.01 in 2025.
  • Its last three reported values are -$1.01 in Q3 2025, -$0.98 for Q2 2025, and -$0.86 during Q1 2025.